Jia C, Lang QF, Yin ZJ, Sun J, Meng QH, Pei TM. Role, mechanism, and application of N6-methyladenosine in hepatobiliary carcinoma. World J Gastrointest Oncol 2025; 17(6): 105140 [DOI: 10.4251/wjgo.v17.i6.105140]
Corresponding Author of This Article
Tie-Min Pei, Chief Physician, Professor, Senior Researcher, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin 150001, Heilongjiang Province, China. tiemin2008@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Chen Jia, Qing-Fu Lang, Zhi-Jie Yin, Jia Sun, Qing-Hui Meng, Tie-Min Pei, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China
Author contributions: Jia C, Lang QF conceived, wrote, and edited the manuscript; Yin ZJ and Sun J prepared figures; Yin ZJ, Sun J, Meng QH and Pei TM provided significant assistance; All authors read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 82172792.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tie-Min Pei, Chief Physician, Professor, Senior Researcher, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No. 23 Postal Street, Nangang District, Harbin 150001, Heilongjiang Province, China. tiemin2008@163.com
Received: January 13, 2025 Revised: April 1, 2025 Accepted: April 22, 2025 Published online: June 15, 2025 Processing time: 152 Days and 3.5 Hours
Abstract
Hepatobiliary carcinoma is a frequently occurring and highly invasive cancer within the digestive tract, known for its rapid progression. Due to its difficult diagnosis and treatment in clinical practice, hepatobiliary carcinoma is a serious threat to human life and health. In recent years, the incidence of hepatobiliary carcinoma has gradually increased. N6-methyladenosine (m6A) modification, as a reversible post-transcriptional modification of the adenosine N6 site, is one of the most important RNA modifications in eukaryotes. Emerging research indicates that m6A affects the biological process of cells through the regulation of gene expression. m6A modification also plays a key role in the occurrence and development of various cancers. This review summarizes the role and mechanism of m6A modification in hepatobiliary carcinoma, and discussed its potential clinical application, so as to provide a theoretical reference for the individualized treatment of hepatobiliary carcinoma.
Core Tip: N6-methyladenine (m6A) modifications is one of the most common RNA modifications in eukaryotes, and it has been reported to affect biological process of cells via regulation of gene expression, and play a crucial role in occurrence and development in various cancers by regulating RNA stability, decay, spicing and transport. This article summarized the role and mechanism of m6A modification in hepatobiliary carcinoma, and discussed its potential clinical application in an attempt to provide theoretical evidences for the individualized treatment of hepatobiliary carcinoma.
